Vaseem Mahboob Sells 26,287 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Key Points

• CFO Vaseem Mahboob sold 26,287 Kestra Medical Technologies shares for approximately $680,308, reducing his direct holdings by 30.25% to 60,609 shares. He also reported four earlier sales totaling 25,183 shares.
• Kestra shares fell 1.6% to $27.90, while the company reported a quarterly loss of $0.67 per share—worse than the $0.59 consensus estimate—on $28.64 million in revenue.
• Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $28.14; institutional investors, including UBS and Sei Investments, recently increased their positions.

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS - Get Free Report) CFO Vaseem Mahboob sold 26,287 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $25.88, for a total transaction of $680,307.56. Following the sale, the chief financial officer directly owned 60,609 shares of the company's stock, valued at approximately $1,568,560.92. This trade represents a 30.25% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $24.68, for a total transaction of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total transaction of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.75, for a total transaction of $90,545.00.

Kestra Medical Technologies Stock Down 1.6%

Shares of NASDAQ:KMTS traded down $0.45 during midday trading on Tuesday, hitting $27.90. 225,985 shares of the company's stock traded hands, compared to its average volume of 344,041. The firm's fifty day moving average price is $23.13 and its two-hundred day moving average price is $22.60. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.41 and a current ratio of 4.41. Kestra Medical Technologies, Ltd. has a twelve month low of $14.40 and a twelve month high of $30.00. The company has a market cap of $1.63 billion, a PE ratio of -11.53 and a beta of 0.58.

Kestra Medical Technologies (NASDAQ:KMTS - Get Free Report) last announced its quarterly earnings results on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.08). Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. The company had revenue of $28.64 million during the quarter. On average, equities research analysts anticipate that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Seven Grand Managers LLC acquired a new position in shares of Kestra Medical Technologies in the 4th quarter valued at approximately $2,652,000. Eventide Asset Management LLC grew its position in shares of Kestra Medical Technologies by 5.4% during the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company's stock worth $33,671,000 after buying an additional 65,288 shares in the last quarter. Sei Investments Co. increased its stake in shares of Kestra Medical Technologies by 22.6% in the first quarter. Sei Investments Co. now owns 237,116 shares of the company's stock worth $4,726,000 after buying an additional 43,753 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new stake in shares of Kestra Medical Technologies in the fourth quarter worth $9,282,000. Finally, UBS Group AG raised its holdings in Kestra Medical Technologies by 34.9% in the fourth quarter. UBS Group AG now owns 270,058 shares of the company's stock valued at $7,162,000 after acquiring an additional 69,908 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. BTIG Research raised their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the company a "buy" rating in a report on Wednesday, July 15th. Wolfe Research set a $30.00 price objective on shares of Kestra Medical Technologies in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of Kestra Medical Technologies from a "sell" rating to a "hold" rating in a research note on Saturday. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a "market perform" rating on the stock. Finally, Weiss Ratings downgraded shares of Kestra Medical Technologies from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, July 16th. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $28.14.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source